Edition:
India

Profile: Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

9.73USD
20 Oct 2017
Change (% chg)

$0.07 (+0.72%)
Prev Close
$9.66
Open
$9.65
Day's High
$9.85
Day's Low
$9.54
Volume
87,104
Avg. Vol
226,264
52-wk High
$25.95
52-wk Low
$5.42

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Company Address

Zynerba Pharmaceuticals Inc

80 W. Lancaster Avenue, Suite 30
DEVON   PA   19333
P: +1484.5817505
F: +1302.6555049

Company Web Links